Phase 2 N=40 Phase 2 Study of VGT-309 in Lung Cancer
Lung Cancer
Primary: Clinically Significant Event (CSE) — 0.425 Proportion of subjects — p=< .0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=25 Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
Paraganglioma · Pheochromocytoma
Primary: Clinical Benefit Rate (CBR) Which is Defined as Either a Partial Response (PR) Complete Response (CR) or Stable Disease (SD) for ≥ 12 Weeks Measured Using Response…
Phase 2 N=21 An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion
Myelodysplastic Syndromes
Primary: Percentage of Participants Who Achieved Hematologic Improvement in Erythroid Response (HI-E) Per International Working Group (IWG) Through Week 24 — 47.6 Percentage of…
Phase 2 N=14 A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer
Squamous Cell Carcinoma of Head and Neck
Primary: Overall Response Rate (ORR) Based on RECIST v1.1 — 0; 16.7 percentage of participants
Phase 2 N=115 A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients
COVID-19
Primary: Time to Sustained Clinical Improvement of at Least 2 Points — 7.0; 7.0 days
Phase 2 N=60 Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)
Chikungunya
Primary: Percentage of Participants With 4-fold Rise in Anti-CHIKV Neutralizing Antibody Response — 100; 100 percentage of participants — p=1
Phase 2 N=146 Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)
Classical Hodgkin Lymphoma
Primary: Complete Response (CR) Rate at the End of Study Intervention as Assessed by Blinded Independent Central Review (BICR) Per Lugano 2014 Response Criteria — 67.0 Percentage…
Phase 2 N=27 A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Overall Response Rate (ORR) — 0.89 proportion of participants
Phase 2 N=47 Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate
Healthy Volunteers
Primary: Resting Energy Expenditure at Low Temperature — 1.277; 1.134; 1.300; 1.271 kcal/min
Phase 2 N=3 A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.
Acute Myeloid Leukemia · FLT3-mutated Acute Myeloid Leukemia
Primary: Phase 1 Part: Maximum Tolerated Dose (MTD) of Gilteritinib — NA miligram (mg)
Phase 2 N=12 Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations
Prostate Cancer Metastatic
Primary: Number of Participants With Prostate Specific Antigen (PSA) >=50 Response — 5 Participants
Phase 2 N=73 Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension
Pulmonary Artery Hypertension
Primary: Change From Baseline in Six Minute Walk Distance (Meters) — 414.5; 461.7; 448.9; 483.0 meters
Phase 2 N=21 TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
Grade 1 Follicular Lymphoma · Grade 2 Follicular Lymphoma · Grade 3a Follicular Lymphoma
Primary: Number of Dose-limiting Toxicity Assessed Using Common Terminology Criteria for Adverse Events Version 4.0 (Phase Ib) — 1; 0 Participants
Phase 2 N=16 Topical Ruxolitinib in Chronic Hand Dermatitis
Chronic Hand Dermatitis
Primary: Proportion of Patients With Chronic Hand Dermatitis Improvement as Assessed by Investigators Global Assessment — 0.53 proportion of participants
Phase 2 N=29 Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat)
Pulmonary Arterial Hypertension
Primary: Area Under the Curve 0-24h (AUC0-24h) (ng.h/mL) - 50 mg — 155; 761; 1570; 172 ng.h/mL